These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27811856)

  • 1. Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours.
    Laskaratos FM; Walker M; Naik K; Maragkoudakis E; Oikonomopoulos N; Grant L; Meyer T; Caplin M; Toumpanakis C
    Br J Cancer; 2016 Nov; 115(11):1321-1327. PubMed ID: 27811856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
    Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
    Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
    Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
    Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
    J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin.
    Jann H; Denecke T; Koch M; Pape UF; Wiedenmann B; Pavel M
    Neuroendocrinology; 2013; 98(2):137-43. PubMed ID: 23797176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.
    Khasraw M; Townsend A; Price T; Hart J; Bell D; Pavlakis N
    Intern Med J; 2010 Jun; 40(6):453-8. PubMed ID: 20636828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.
    Rinke A; Wittenberg M; Schade-Brittinger C; Aminossadati B; Ronicke E; Gress TM; Müller HH; Arnold R;
    Neuroendocrinology; 2017; 104(1):26-32. PubMed ID: 26731483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
    Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
    Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
    Tadman M; Charlton P; Jafar-Mohammadi B; Talbot D; Grossman AB
    Endocr Pract; 2018 Feb; 24(2):189-194. PubMed ID: 29466059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
    Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
    Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
    Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.
    Shen C; Xu Y; Dasari A; Shih YC; Yao JC
    Oncologist; 2016 Mar; 21(3):308-13. PubMed ID: 26911407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
    Lau SC; Abdel-Rahman O; Cheung WY
    Med Oncol; 2018 Aug; 35(9):123. PubMed ID: 30078166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.
    Pusceddu S; Prinzi N; Raimondi A; Corti F; Buzzoni R; Di Bartolomeo M; Seregni E; Maccauro M; Coppa J; Milione M; Mazzaferro V; de Braud F
    Tumori; 2019 Apr; 105(2):113-120. PubMed ID: 29714658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.
    Strosberg J; Kvols L
    World J Gastroenterol; 2010 Jun; 16(24):2963-70. PubMed ID: 20572298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.